Volume 1: Issue 3

The scientific program of the Pulmonary Hypertension Association is guided by the association's Scientific Leadership Council. The Council includes the following health care professionals:

Michael McGoon, MD, SLC Chair, Pulmonary Hypertension Clinic, Mayo Clinic, Rochester, Minnesota
Robyn Barst, MD, SLC Vice-Chair, Columbia Presbyterian Medical Center, Babies Hospital, New York, New York
David B. Badesch, MD, Chair, SLC Nominations Committee, University of Colorado Health Sciences Center, Denver, Colorado
Joy Beckmann, RN, MSN, Pulmonary Hypertension Program, Harbor-UCLA Medical Center, Torrance, California
C. Gregory Elliott, MD, Chair, SLC Publications Committee, LDS Hospital, University of Utah School of Medicine,

Ivan Robbins, MD, Director, Pulmonary Hypertension Center, Vanderbilt University, Nashville, Tennessee, conducted this discussion. The panel included David Langleben, MD, Director, Center for Pulmonary Vascular Disease, Jewish General Hospital, McGill University, Montreal, Quebec, Canada; Michael McGoon, MD, Consultant in Cardiology, Mayo Clinic, Rochester, Minnesota; and Abby Krichman, RRT, Pulmonary Hypertension Coordinator, Duke University Medical Center, Durham, North Carolina.

The Scientific Leadership Council of the Pulmonary Hypertension Association

The Prostacyclin Story: From Discovery to Future Directions

A Nobel Prize Winner Who Triggered a Revolution in Therapy

Continuous Intravenous Epoprostenol for Pulmonary Arterial Hypertension: Highlighting Practical Issues, Special Considerations

Oral and Subcutaneous Prostacyclin Analogs: Analyzing the Latest Evidence on Efficacy and Safety

Inhaled Iloprost for Treatment of Pulmonary Arterial Hypertension

Bench to Bedside: Principles and Practice of Epoprostenol Therapy, from Maximizing Benefit to Minimizing Side Effects

Racial and Ethnic Equity in Pulmonary Arterial Hypertension Clinical Trials

Multiomics Integration for Identifying Treatment Targets, Drug Development, and Diagnostic Designs in PAH

Tyrosine Kinase Inhibitors for Treatment of Pulmonary Arterial Hypertension

Full Issue PDF

Editor’s Memo